$ATXI News

Last published 1y ago

1y agoATXI FBIOAvenue Therapeutics Reports Third Quarter 2024 Financial Results and Recent Corporate HighlightsGlobeNewswireMIAMI, Nov. 14, 2024 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (NASDAQ:ATXI) ("Avenue" or the "Company"), a specialty pharmaceutical company focused on the development and commercialization of therapies for the
2y agoATXI FBIOAvenue Therapeutics to Participate in Maxim Group's 2024 Healthcare Virtual SummitGlobeNewswireMIAMI, Oct. 09, 2024 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (NASDAQ:ATXI) ("Avenue" or the "Company"), a specialty pharmaceutical company focused on the development and commercialization of therapies for the
2y agoATXI FBIOAvenue Therapeutics to Participate in Upcoming Investor ConferencesGlobeNewswireMIAMI, Sept. 03, 2024 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (NASDAQ:ATXI) ("Avenue" or the "Company"), a specialty pharmaceutical company focused on the development and commercialization of therapies for the
2y agoATXI CKPT DERM FBIO+1Fortress Biotech Reports Second Quarter 2024 Financial Results and Recent Corporate HighlightsGlobeNewswirePDUFA goal date of November 4, 2024 for DFD-29 for the treatment of inflammatory lesions and erythema of rosacea in adults FDA accepted Biologics License Application resubmission for cosibelimab to treat metastatic or
2y agoATXI FBIOAvenue Therapeutics Reports Second Quarter 2024 Financial Results and Recent Corporate HighlightsGlobeNewswire- Last patient visit complete in Phase 1b/2a clinical trial of AJ201 for spinal and bulbar muscular atrophy; topline data anticipated in second half of 2024 – - Raised $4.4 million in gross proceeds from a May 2024
2y agoATXI FBIOAvenue Therapeutics to Present at the H.C. Wainwright 5th Annual Neuro Perspectives Virtual ConferenceGlobeNewswireMIAMI, June 20, 2024 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (NASDAQ:ATXI) ("Avenue" or the "Company"), a specialty pharmaceutical company focused on the development and commercialization of therapies for the
2y agoATXI FBIOAvenue Therapeutics Announces Last Patient Last Visit in Phase 1b/2a Clinical Trial of AJ201 for the Treatment of Spinal and Bulbar Muscular Atrophy (Kennedy's Disease)GlobeNewswireMIAMI, May 16, 2024 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (NASDAQ:ATXI) ("Avenue" or the "Company"), a specialty pharmaceutical company focused on the development and commercialization of therapies for the
2y agoATXI FBIOAvenue Therapeutics Reports First Quarter 2024 Financial Results and Recent Corporate HighlightsGlobeNewswire– Raised a total of $9.4 million in gross proceeds from warrant exercise transactions since January 2024 – MIAMI, May 15, 2024 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (NASDAQ:ATXI) ("Avenue" or the "Company"), a
2y agoATXI FBIOAvenue Therapeutics Announces Exercise of Warrants for $4.4 Million in Gross ProceedsGlobeNewswireMIAMI, April 29, 2024 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (NASDAQ:ATXI) ("Avenue" or the "Company"), a specialty pharmaceutical company focused on the development and commercialization of therapies for the
2y agoATXI FBIOAvenue Therapeutics Announces Reverse Stock SplitGlobeNewswireMIAMI, April 24, 2024 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (NASDAQ:ATXI) ("Avenue" or the "Company"), a specialty pharmaceutical company focused on the development and commercialization of therapies for the
2y agoATXI FBIOAvenue Therapeutics to Host Virtual Key Opinion Leader (KOL) Event on April 4, 2024GlobeNewswireMIAMI, March 25, 2024 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (NASDAQ:ATXI) ("Avenue" or the "Company"), a specialty pharmaceutical company focused on the development and commercialization of therapies for the
2y agoATXI FBIOAvenue Therapeutics Reports Full Year 2023 Financial Results and Recent Corporate HighlightsGlobeNewswire- Enrollment completed in Phase 1b/2a clinical trial of AJ201 for spinal and bulbar muscular atrophy; topline data expected in second quarter of 2024 - - Presented positive BAER-101 preclinical data at American
2y agoATXI FBIOAvenue Therapeutics Receives Positive Listing Determination from NasdaqGlobeNewswireMIAMI, March 15, 2024 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (NASDAQ:ATXI) ("Avenue" or the "Company"), a specialty pharmaceutical company focused on the development and commercialization of therapies for the
2y agoATXI FBIOAvenue Therapeutics to Present BAER-101 Preclinical Data at American Society for Experimental Neurotherapeutics (ASENT) 2024 Annual MeetingGlobeNewswireBAER-101 demonstrated full suppression of seizure activity in SynapCell's GAERS model of absence epilepsy, a proven indicator of efficacy in anti-seizure drug development with high predictability of response in
2y agoATXI FBIOAvenue Therapeutics Announces Publication in Drug Development Research Highlighting First-In-Class Preclinical Data of BAER-101 in a Translational Model of Absence EpilepsyGlobeNewswireMIAMI, Feb. 22, 2024 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (NASDAQ:ATXI) ("Avenue" or the "Company"), a specialty pharmaceutical company focused on the development and commercialization of therapies for the
2y agoADES APOG ATXI BTM+13Sidoti Events, LLC's Virtual January Micro-Cap ConferenceACCESS NewswireNEW YORK, NY / ACCESSWIRE / January 16, 2024 / Sidoti Events, LLC, an affiliate of Sidoti & Company, LLC, has released the presentation schedule and weblinks for its two-day January Micro-Cap Conference taking place
2y agoATXI FBIOAvenue Therapeutics to Present at Sidoti January Micro-Cap Investor ConferenceGlobeNewswireMIAMI, Jan. 11, 2024 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (NASDAQ:ATXI) ("Avenue" or the "Company"), a specialty pharmaceutical company focused on the development and commercialization of therapies for the
2y agoATXI FBIOAvenue Therapeutics Enters into Warrant Exercise Transactions for $5.0 Million in ProceedsGlobeNewswireMIAMI, Jan. 05, 2024 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (NASDAQ:ATXI) ("Avenue" or the "Company"), a specialty pharmaceutical company focused on the development and commercialization of therapies for the
2y agoATXI FBIOAvenue Therapeutics Reaches Final Agreement with the U.S. FDA for the Phase 3 Safety Study for IV TramadolGlobeNewswireMIAMI, Jan. 04, 2024 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (NASDAQ:ATXI) ("Avenue" or the "Company"), a specialty pharmaceutical company focused on the development and commercialization of therapies for the
2y agoATXI FBIOAvenue Therapeutics Announces Completion of Enrollment in Phase 1b/2a Clinical Trial of AJ201 for the Treatment of Spinal and Bulbar Muscular Atrophy (Kennedy's Disease)GlobeNewswire- Topline data remains on track for second quarter of 2024 - MIAMI, Jan. 02, 2024 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (NASDAQ:ATXI) ("Avenue" or the "Company"), a specialty pharmaceutical company focused
2y agoATXI FBIOAvenue Therapeutics to Present at American Epilepsy Society 2023 Annual MeetingGlobeNewswireMIAMI, Dec. 01, 2023 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (NASDAQ:ATXI) ("Avenue" or the "Company"), a specialty pharmaceutical company focused on the development and commercialization of therapies for the
2y agoATXI FBIOAvenue Therapeutics Reports Third Quarter 2023 Financial Results and Recent Corporate HighlightsGlobeNewswire- Phase 1b/2a clinical trial of AJ201 remains on track to report topline data in second quarter of 2024 - - Positive BAER-101 preclinical data accepted for presentation at American Epilepsy Society (AES) Annual Meeting
3y agoATXI FBIOAvenue Therapeutics Announces Closing of $5.0 Million Public OfferingGlobeNewswireMIAMI, Nov. 02, 2023 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (NASDAQ:ATXI) ("Avenue" or the "Company"), a specialty pharmaceutical company focused on the development and commercialization of therapies for the
3y agoATXI FBIOAvenue Therapeutics Announces Pricing of $5.0 Million Public OfferingGlobeNewswireMIAMI, Oct. 31, 2023 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (NASDAQ:ATXI) ("Avenue" or the "Company"), a specialty pharmaceutical company focused on the development and commercialization of therapies for the
3y agoATXI FBIOAvenue Therapeutics to Present at H.C. Wainwright 25th Annual Global Investment ConferenceGlobeNewswireMIAMI, Sept. 05, 2023 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (NASDAQ:ATXI) ("Avenue" or the "Company"), a specialty pharmaceutical company focused on the development and commercialization of therapies for the
3y agoATXI CKPT DERM FBIO+1Fortress Biotech Reports Second Quarter 2023 Financial Results and Recent Corporate HighlightsGlobeNewswireTotal net revenue was $17.4 million in the second quarter of 2023, a 40% increase from $12.4 million in the first quarter of 2023 Positive topline results from two Phase 3 clinical trials evaluating DFD-29
3y agoATXI FBIOAvenue Therapeutics Reports Second Quarter 2023 Financial Results and Recent Corporate HighlightsGlobeNewswire- First patient dosed in Phase 1b/2a clinical trial of AJ201; topline data anticipated in first half of 2024 - - Positive BAER-101 preclinical data demonstrate excellent anti-seizure activity in translational animal
3y agoATXI FBIOAvenue Therapeutics Announces High Potency and Full Efficacy in a Model of Generalized Seizures for its Novel GABA-A Receptor Potentiator, BAER-101, Supporting Phase 2 Clinical StudyGlobeNewswireMIAMI, Aug. 01, 2023 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (NASDAQ:ATXI) ("Avenue" or the "Company"), a specialty pharmaceutical company focused on the development and commercialization of therapies for the
3y agoATXI FBIOAvenue Therapeutics Announces First Patient Dosed in Phase 1b/2a Clinical Trial of AJ201 for the Treatment of Spinal and Bulbar Muscular Atrophy (Kennedy's Disease)GlobeNewswireMIAMI, July 27, 2023 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (NASDAQ:ATXI) ("Avenue" or the "Company"), a specialty pharmaceutical company focused on the development and commercialization of therapies for the
3y agoATXI FBIOAvenue Therapeutics Announces Agreement with the FDA on the Study Design and Analysis Approach of the Phase 3 Safety Study for IV TramadolGlobeNewswireMIAMI, July 25, 2023 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (NASDAQ:ATXI) ("Avenue" or the "Company"), a specialty pharmaceutical company focused on the development and commercialization of therapies for the
3y agoABEO ALLR ATXI ICPTAllarity Therapeutics Strengthens Board of Directors with Appointment of Three Accomplished Biotechnology ExecutivesGlobeNewswireNew appointments bring therapeutic development expertise and proven leadership to support continued progress of Allarity's multiple oncology clinical programs BOSTON (July 24, 2023) — Allarity Therapeutics, Inc.
3y agoATXI CKPT DERM FBIO+1Fortress Biotech Reports First Quarter 2023 Financial Results and Recent Corporate HighlightsGlobeNewswireFortress is advancing several late-stage clinical assets with two NDA submissions anticipated in second half of 2023 PDUFA goal date of January 3, 2024 set by FDA for cosibelimab to treat metastatic or locally advanced
3y agoATXI FBIOAvenue Therapeutics Reports First Quarter 2023 Financial Results and Recent Corporate HighlightsGlobeNewswireMIAMI, May 12, 2023 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (NASDAQ:ATXI) ("Avenue" or the "Company"), a specialty pharmaceutical company focused on the development and commercialization of therapies for the
3y agoATXI FBIOAvenue Therapeutics to Present at Aegis Capital Virtual ConferenceGlobeNewswireMIAMI, April 27, 2023 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (NASDAQ:ATXI) ("Avenue" or the "Company"), a specialty pharmaceutical company focused on the development and commercialization of therapies for the
3y agoATXI FBIOAvenue Therapeutics Announces Regulatory Update Based on Type C Meeting with FDA and Next Steps in the Development of IV TramadolGlobeNewswireMIAMI, April 17, 2023 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (NASDAQ:ATXI) ("Avenue" or the "Company"), a specialty pharmaceutical company focused on the development and commercialization of therapies for the
3y agoATXI CKPT DERM FBIO+1Fortress Biotech Reports Record 2022 Financial Results and Recent Corporate HighlightsGlobeNewswireFortress expects to file a total of three new drug applications in 2023 Record consolidated net revenue of $75.7 million for full-year 2022 FDA accepted for filing the Biologics License Application for cosibelimab in
3y agoATXI FBIOAvenue Therapeutics Reports Full Year 2022 Financial Results and Recent Corporate HighlightsGlobeNewswireMIAMI, March 30, 2023 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (NASDAQ:ATXI) ("Avenue" or the "Company"), a specialty pharmaceutical company focused on the development and commercialization of therapies for the
3y agoATXIAnnJi Pharmaceutical Announced A Licensing Agreement With Avenue Therapeutics To Develop And Commercialize AJ201, A First-In-Class Clinical Asset For The Treatment Of Kennedy's DiseasePR NewswireTAIPEI, March 10, 2023 /PRNewswire/ -- AnnJi Pharmaceutical Co. (AnnJi) has entered into an exclusive license agreement with Avenue Therapeutics Inc. ((Avenue, NASDAQ:ATXI) for the development and commercialization of
3y agoATXI FBIOAvenue Therapeutics Provides Regulatory Update on IV Tramadol and Other Corporate UpdatesGlobeNewswireMIAMI, March 08, 2023 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (NASDAQ:ATXI) ("Avenue" or the "Company"), a specialty pharmaceutical company focused on the development and commercialization of therapies for the
3y agoATXI FBIOAvenue Therapeutics Enters into a Transformational License Agreement with AnnJi Pharmaceutical to Develop and Commercialize AJ201, a First-in-Class Clinical Asset for the Treatment of Spinal and Bulbar Muscular AtrophyGlobeNewswireMIAMI, March 02, 2023 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (NASDAQ:ATXI) ("Avenue" or the "Company"), a specialty pharmaceutical company focused on the development and commercialization of therapies for the
3y agoATXI FBIOAvenue Therapeutics Announces Closing of $3.25 Million Registered Direct and Private PlacementGlobeNewswireMIAMI, Jan. 31, 2023 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (NASDAQ:ATXI) ("Avenue" or the "Company"), a specialty pharmaceutical company focused on the development and commercialization of therapies for the
3y agoATXI FBIOAvenue Therapeutics Announces $3.25 Million Registered Direct and Private Placement Priced at the Market Under Nasdaq RulesGlobeNewswireMIAMI, Jan. 27, 2023 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (NASDAQ:ATXI) ("Avenue" or the "Company"), a specialty pharmaceutical company focused on the development and commercialization of therapies for the
4y agoATXI FBIOAvenue Therapeutics Reports Third Quarter 2022 Financial Results and Recent Corporate HighlightsGlobeNewswireNEW YORK, Nov. 10, 2022 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (NASDAQ:ATXI) ("Avenue" or the "Company"), a specialty pharmaceutical company focused on the development and commercialization of therapies for the
4y agoATXI FBIOAvenue Therapeutics Completes the Acquisition of Baergic Bio and its Selective GABA-A α2/3 Receptor Positive Allosteric Modulator for the Treatment of Central Nervous System DisordersGlobeNewswireNEW YORK, Nov. 08, 2022 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (NASDAQ:ATXI) ("Avenue" or the "Company"), a specialty pharmaceutical company focused on the development and commercialization of therapies for the
4y agoATXIAvenue Therapeutics Announces Closing of $12 Million Underwritten Public OfferingGlobeNewswireNEW YORK, Oct. 11, 2022 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (NASDAQ:ATXI) ("Avenue" or the "Company"), a specialty pharmaceutical company focused on the development and commercialization of therapies for the
4y agoATXIAvenue Therapeutics Announces Pricing of $12 Million Underwritten Public OfferingGlobeNewswireNEW YORK, Oct. 06, 2022 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (NASDAQ:ATXI) ("Avenue" or the "Company"), a specialty pharmaceutical company focused on the development and commercialization of therapies for the
4y agoATXI FBIOUrica Therapeutics Appoints Seasoned Biotech Executive Jay D. Kranzler, M.D., Ph.D., as Chairman and Chief Executive OfficerGlobeNewswireMIAMI, Oct. 03, 2022 (GLOBE NEWSWIRE) -- Urica Therapeutics, Inc. ("Urica" or the "Company") (formerly known as UR-1 Therapeutics, Inc.), a Fortress Biotech, Inc. (NASDAQ:FBIO) ("Fortress") subsidiary company focused on the development and commercializ
4y agoATXIAvenue Therapeutics Announces Reverse Stock Split and Provides Regulatory Update for IV Tramadol Including Receipt of Type A Meeting Minutes from the FDAGlobeNewswireNEW YORK, Sept. 22, 2022 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (NASDAQ:ATXI) ("Avenue" or the "Company"), a specialty pharmaceutical company focused on the development and commercialization of therapies for the treatment of central nervous syst
4y agoABEO ATXIAbeona Therapeutics Announces Strategy Update and 2021 Financial ResultsGlobeNewswireEB-101 pivotal phase 3 VIITAL™ study in RDEB achieves target enrollment; top-line data expected in third quarter of 2022; gained FDA alignment on CMC requirements for EB-101 including characterization and validation plans Company to focus R&D resour
4y agoATXIAvenue Therapeutics Announces Outcome of FDA Advisory Committee Meeting on IV TramadolGlobeNewswireNEW YORK, Feb. 15, 2022 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (NASDAQ:ATXI) ("Avenue"), a company focused on the development of intravenous ("IV") tramadol for the U.S. market, today announced the outcome of the U.S. Food and Drug Administratio